Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Passenger Missing After Going Overboard Disney Cruise Ship - 22024 Eurovision winner Nemo returns trophy over Israel's participation
- 3Insurance warning signs in doctors’ offices might discourage patients from speaking openly about their health
- 4Israeli president concerned over proposed renaming of park
- 5Instructions to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- 'Inflaming tensions': Bedouin mayor slams Ben-Gvir's unauthorized visit after meeting cancellation
- From Sea shores to Urban areas: Astonishing Worldwide Travel Objections
- RFK Jr. says he's following 'gold standard' science. Here's what to know
- ‘Democratizing space’ is more than just adding new players – it comes with questions around sustainability and sovereignty
- Top 20 Wellbeing and Wellness Applications for a Sound Way of life
- Select Your Definitive Pizza Decision
- A coup too far: Why Benin's rebel soldiers failed where others in the region succeeded
- RFK Jr. says fewer flu shots for kids may be 'better.' What experts say.
- UN chief warns he could refer Israel to ICJ over laws targetting UNRWA
